Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.

Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.

Abstract: A thiazole compound represented by general formula (I), wherein R is hydrogen atom, a hydroxy group, a straight or branched C.sub.1 -C.sub.6 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C.sub.1 -C.sub.5 alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula: NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4, identical to or different from each other, represent independently a hydrogen atom, a C.sub.1 -C.sub.6 lower alkyl group, a C.sub.3 -C.sub.

Abstract: Novel 4-amino-3-acylnaphthyridine derivatives represented by formula (I), wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 lower alkoxy group, C.sub.1 -C.sub.6 lower alkoxyalkyl group, C.sub.3 -C.sub.6 cycloalkyl group, C.sub.3 -C.sub.6 cycloalkyl C.sub.1 -C.sub.6 alkyl group, a or phenyl group which maybe substituted with C.sub.1 -C.sub.6 alkyl group; R.sub.2 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, or a group of the formula: NR.sub.6 R.sub.7 wherein R.sub.6 and R.sub.7, identical to or different from each other, are independently hydrogen or C.sub.1 -C.sub.6 lower alkyl group, or R.sub.6 and R.sub.7 may form together 5-membered or 6-membered cycloalkyl group; R.sub.3 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, an amino group substituted with one or two C.sub.1 -C.sub.6 alkyl groups, halogen, cyano group, C.sub.1 -C.sub.